Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$BCTX News Alert: BriaCell Therapeutics (Nasdaq: BCTX, BCTXW)
plans to spin-out certain pre-clinical assets into a newly created entity, SpinCo.
Shareholders will be receiving one new share of SpinCo for each current share of BriaCell held.
Find out more here: https://finance.yahoo.com/news/briacell-announces-intention-spin-certain-124500496.html
#Stocks #StocksToWatch
$BCTX News Alert: BriaCell Therapeutics (Nasdaq: BCTX, BCTXW) plans to spin-out certain pre-clinical assets into a newly created entity, SpinCo.
Shareholders will be receiving one new share of SpinCo for each current share of BriaCell held.
Find out more here: https://finance.yahoo.com/news/briacell-announces-intention-spin-certain-124500496.html
#Stocks #StocksToWatch
$BCTX
News Alert: BriaCell Therapeutics (Nasdaq: BCTX, BCTXW) plans to spin-out certain pre-clinical assets into a newly created entity, SpinCo.
Shareholders will be receiving one new share of SpinCo for each current share of BriaCell held.
Find out more here: https://finance.yahoo.com/news/briacell-announces-intention-spin-certain-124500496.html
#Stocks #StocksToWatch
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) will be sharing "refreshed survival updates, new patient data, and potential late-breaking discoveries."
BriaCell Therapeutics Corp. to Present Clinical and Survival Data in Advanced Metastatic Breast Cancer at the 2023 AACR Annual Meeting.
Read their press release for more information: https://globenewswire.com/news-release/2023/03/15/2627787/0/en/BriaCell-to-Present-Clinical-and-Survival-Data-in-Advanced-Metastatic-Breast-Cancer-at-the-2023-AACR-Annual-Meeting.html
#Stocks #StocksInFocus #StocksToWatch #Conventions #CancerResearch
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) will be sharing "refreshed survival updates, new patient data, and potential late-breaking discoveries."
BriaCell Therapeutics Corp. to Present Clinical and Survival Data in Advanced Metastatic Breast Cancer at the 2023 AACR Annual Meeting.
Read their press release for more information: https://globenewswire.com/news-release/2023/03/15/2627787/0/en/BriaCell-to-Present-Clinical-and-Survival-Data-in-Advanced-Metastatic-Breast-Cancer-at-the-2023-AACR-Annual-Meeting.html
#Stocks #StocksInFocus #StocksToWatch #Conventions #CancerResearch
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) will be sharing "refreshed survival updates, new patient data, and potential late-breaking discoveries."
BriaCell Therapeutics Corp. to Present Clinical and Survival Data in Advanced Metastatic Breast Cancer at the 2023 AACR Annual Meeting.
Read their press release for more information: https://globenewswire.com/news-release/2023/03/15/2627787/0/en/BriaCell-to-Present-Clinical-and-Survival-Data-in-Advanced-Metastatic-Breast-Cancer-at-the-2023-AACR-Annual-Meeting.html
#Stocks #StocksInFocus #StocksToWatch #Conventions #CancerResearch
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) to Present Clinical and Survival Data in Advanced Metastatic Breast Cancer at the 2023 AACR Annual Meeting.
Read their press release for more information: https://globenewswire.com/news-release/2023/03/15/2627787/0/en/BriaCell-to-Present-Clinical-and-Survival-Data-in-Advanced-Metastatic-Breast-Cancer-at-the-2023-AACR-Annual-Meeting.html
#Stocks #StocksInFocus #StocksToWatch
Fantastic news out of BriaCell Therapeutics Corp. (Nasdaq: $BCTX, $BCTXW) today.
BriaCell Reports Positive Survival Data in Advanced Metastatic Breast Cancer.
Read their press release for more information: https://yhoo.it/3IsHStJ
#Stocks #StocksToWatch #BioTech
Fantastic news out of BriaCell Therapeutics Corp. (Nasdaq: $BCTX, $BCTXW) today.
BriaCell Reports Positive Survival Data in Advanced Metastatic Breast Cancer.
Read their press release for more information: https://yhoo.it/3IsHStJ
#Stocks #StocksToWatch #BioTech
Fantastic news out of BriaCell Therapeutics Corp. (Nasdaq: $BCTX, $BCTXW) today.
BriaCell Reports Positive Survival Data in Advanced Metastatic Breast Cancer.
Read their press release for more information: https://yhoo.it/3IsHStJ
#Stocks #StocksToWatch #BioTech
SusGlobal Energy Corp. (OTCQB: SNRG). CEO Marc Hazout Discusses Carbon Credits, Converting Waste, and Renewable Energy.
Listen now: https://bit.ly/3xbTU5u
#circulareconomy #GreenEnergy #Energy #renewable #Sustainability #stocks #StocksToBuy $SNRG
SusGlobal Energy Corp. (OTCQB: SNRG). CEO Marc Hazout Discusses Carbon Credits, Converting Waste, and Renewable Energy.
Listen now: https://bit.ly/3xbTU5u
#circulareconomy #GreenEnergy #Energy #renewable #Sustainability #stocks #StocksToBuy $SNRG
SusGlobal Energy Corp. (OTCQB: SNRG). CEO Marc Hazout Discusses Carbon Credits, Converting Waste, and Renewable Energy.
Listen now: https://bit.ly/3xbTU5u
#circulareconomy #GreenEnergy #Energy #renewable #Sustainability #stocks #StocksToBuy $SNRG
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) was featured in an article on Seeking Alpha
Discover more about this #BioTech company here: https://bit.ly/3DoEbUc
BriaCell Therapeutics: Fast-Tracking High-Potential Breast Cancer Immunotherapy
#Stocks #StocksToWatch
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) was featured in an article on Seeking Alpha
Discover more about this #BioTech company here: https://bit.ly/3DoEbUc
BriaCell Therapeutics: Fast-Tracking High-Potential Breast Cancer Immunotherapy
#Stocks #StocksToWatch
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) was featured in an article on Seeking Alpha
Discover more about this #BioTech company here: https://bit.ly/3DoEbUc
BriaCell Therapeutics: Fast-Tracking High-Potential Breast Cancer Immunotherapy
#Stocks #StocksToWatch
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) was featured in an article on Seeking Alpha
Discover more about this #BioTech company here: https://bit.ly/3DoEbUc
BriaCell Therapeutics: Fast-Tracking High-Potential Breast Cancer Immunotherapy
#Stocks #StocksToWatch
(Nasdaq, CSE: CMND) (FSE: CWY) Israel-Based Clearmind Medicine Inc. Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum.
Read the full press release here: https://finance.yahoo.com/news/israel-based-clearmind-successfully-completed-140000072.html
#Stocks #BioTech
(Nasdaq, CSE: CMND) (FSE: CWY) Israel-Based Clearmind Medicine Inc. Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum.
Read the full press release here: https://finance.yahoo.com/news/israel-based-clearmind-successfully-completed-140000072.html
#Stocks #BioTech
(Nasdaq, CSE: CMND) (FSE: CWY) Israel-Based Clearmind Medicine Inc. Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum.
Read the full press release here: https://finance.yahoo.com/news/israel-based-clearmind-successfully-completed-140000072.html
#Stocks #BioTech
For BriaCell Therapeutics Corp. (Nasdaq: $BCTX, $BCTXW) (TSX: $BCT) latest media coverage, head over to their website here: https://briacell.com/media-coverage/
#Stocks #StocksToWatch #Nasdaq #BioTech
For BriaCell Therapeutics Corp. (Nasdaq: $BCTX, $BCTXW) (TSX: $BCT) latest media coverage, head over to their website here: https://briacell.com/media-coverage/
#Stocks #StocksToWatch #Nasdaq #BioTech
For BriaCell Therapeutics Corp. (Nasdaq: $BCTX, $BCTXW) (TSX: $BCT) latest media coverage, head over to their website here: https://briacell.com/media-coverage/
#Stocks #StocksToWatch #Nasdaq #BioTech
News out of BriaCell Therapeutics Corp. (Nasdaq: $BCTX) this morning!
BriaCell Announces Positive Clinical and Quality of Life Data in Advanced Metastatic Breast Cancer at 2022 San Antonio Breast Cancer Symposium.
Read their press release: https://bit.ly/3hdbMZB
#BioTech
News out of BriaCell Therapeutics Corp. (Nasdaq: $BCTX) this morning!
BriaCell Announces Positive Clinical and Quality of Life Data in Advanced Metastatic Breast Cancer at 2022 San Antonio Breast Cancer Symposium.
Read their press release: https://bit.ly/3hdbMZB
#BioTech
News out of BriaCell Therapeutics Corp. (Nasdaq: $BCTX) this morning!
BriaCell Announces Positive Clinical and Quality of Life Data in Advanced Metastatic Breast Cancer at 2022 San Antonio Breast Cancer Symposium.
Read their press release: https://bit.ly/3hdbMZB
#BioTech
News out of BriaCell Therapeutics Corp. (Nasdaq: $BCTX) this morning!
BriaCell Announces Positive Clinical and Quality of Life Data in Advanced Metastatic Breast Cancer at 2022 San Antonio Breast Cancer Symposium.
Read their press release: https://bit.ly/3hdbMZB
#BioTech
News out of BriaCell Therapeutics Corp. (Nasdaq: $BCTX) this morning!
BriaCell Announces Positive Clinical and Quality of Life Data in Advanced Metastatic Breast Cancer at 2022 San Antonio Breast Cancer Symposium.
Read their press release: https://bit.ly/3hdbMZB
#BioTech
$SIRC Revenue Grew 333% to $57.3 Million with Net Income of $6.2 Million;
Filing of Form 10 Registration Statement Represents Key Milestone Achievement in Uplisting Strategy
Key Operational and Financial Highlights
Revenue in the third quarter increased 333% to $57.3 million, as compared to $13.2 million in the third quarter of 2021.
Net income in the third quarter increased to $6.2 million, or $0.01 per diluted share, as compared to a net loss of $1.7 million, or $(0.00) per diluted share, in the third quarter of 2021.
Revenue expected to be realized from remaining performance obligations for commercial solar contracts totaled $291.6 million as of September 30, 2022.
Filed a Form 10 Registration Statement with the U.S. Securities and Exchange Commission to register its common stock under the Securities Exchange Act of 1934; Transition to a fully reporting company represents a key milestone towards the Company’s goal of a NASDAQ listing.
$SNRG Hall of Fame Golfer Ernie Els Signs Brand Endorsement Agreement with SUSGLOBAL.
This endorsement paves the way for SusGlobal Energy Corp. (OTCQB: SNRG) to market to a vertical projected to reach nearly $25 billion by 2024: https://bit.ly/3V5aJcx
#Stocks #StocksToWatch
(OTCQB: SNRG) Hall of Fame Golfer Ernie Els Signs Brand Endorsement Agreement with SUSGLOBAL.
This endorsement paves the way for SusGlobal Energy Corp. (OTCQB: SNRG) to market to a vertical projected to reach nearly $25 billion by 2024: https://bit.ly/3V5aJcx
#Stocks #StocksToWatch #OTCQB #OTCMarkets
SusGlobal Energy Corp. (OTCQB: SNRG) to market to a vertical projected to reach nearly $25 billion by 2024: https://bit.ly/3V5aJcx
Hall of Fame Golfer Ernie Els Signs Brand Endorsement Agreement with SUSGLOBAL.
BriaCell Reports Positive Breast Cancer Efficacy Data with Bria-IMT™ Immunotherapy Treatment at SITC Annual Meeting!
The study was recently awarded U.S. Food and Drug Administration ("FDA") fast track designation.
Read their press release from this morning for all the details: https://bit.ly/3UszlMc
#Stocks #Nasdaq #StocksToWatch
BriaCell Reports Positive Breast Cancer Efficacy Data with Bria-IMT™ Immunotherapy Treatment at SITC Annual Meeting!
The study was recently awarded U.S. Food and Drug Administration ("FDA") fast track designation.
Read their press release from this morning for all the details: https://bit.ly/3UszlMc
#Stocks #Nasdaq #StocksToWatch
A Breakthrough in Cancer Treatment from BriaCell Therapeutics Corp. (Nasdaq: BCTX)
Bria-IMT™ regimen in combination with Incyte’s retifanlimab produced evidence of disease control, tumor shrinkage, and potential survival benefit amongst BriaCell’s recent 12 patient cohort in advanced breast cancer.
The regimen remains well tolerated as recently reported in Phase I evaluation.
70% of patients showed either disease control or progression-free survival (PFS) benefits compared with their last therapy.
Prior to enrollment, the 12 patients in the cohort had already been unsuccessfully heavily pre-treated with at least 2 prior therapy regimens, further underscoring BriaCell’s positive patient outcomes.
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce positive initial efficacy data in its 2021-2022 cohort of 12 advanced breast cancer patients. Disease control, tumor shrinkage, and potential survival benefit were observed amongst 12 patients in the Phase I/IIa clinical study of Bria-IMT™ in combination with Incyte’s retifanlimab.
“We are very pleased to report that our combination therapy with Incyte’s retifanlimab produced clear evidence of tumor shrinkage and showed potential survival benefit in heavily pre-treated advanced breast cancer patients,” stated Dr. William V. Williams, BriaCell’s President & CEO. “We interpret these results to offer a potential opportunity for treatment in otherwise terminal patients. It’s very important to emphasize that these responses and clinical benefit occurred in women with advanced-stage breast cancer who have exhausted other treatment options.”
This information is summarized in BriaCell’s poster session at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, held November 10-12, 2022, in Boston, Massachusetts. The poster session highlights BriaCell’s novel off-the-shelf personalized cellular therapy approach to immunotherapy treatment.
Title: An off-the-shelf personalized cellular approach to immunotherapy for the treatment of advanced solid tumors.
Abstract Number: 257
Location: Omni Boston Hotel, 450 Summer Street, Boston, Massachusetts 02210, Poster Hall, Hall C
Date and Time: November 10, 2022, 9:00 am – 9:00 pm
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) BOOM!
BriaCell Reports Positive Breast Cancer Efficacy Data with Bria-IMT™ Immunotherapy Treatment at SITC Annual Meeting
Bria-IMT™ regimen in combination with Incyte’s retifanlimab produced evidence of disease control, tumor shrinkage, and potential survival benefit amongst BriaCell’s recent 12 patient cohort in advanced breast cancer.
The regimen remains well tolerated as recently reported in Phase I evaluation.
70% of patients showed either disease control or progression-free survival (PFS) benefits compared with their last therapy.
Prior to enrollment, the 12 patients in the cohort had already been unsuccessfully heavily pre-treated with at least 2 prior therapy regimens, further underscoring BriaCell’s positive patient outcomes.
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce positive initial efficacy data in its 2021-2022 cohort of 12 advanced breast cancer patients. Disease control, tumor shrinkage, and potential survival benefit were observed amongst 12 patients in the Phase I/IIa clinical study of Bria-IMT™ in combination with Incyte’s retifanlimab.
“We are very pleased to report that our combination therapy with Incyte’s retifanlimab produced clear evidence of tumor shrinkage and showed potential survival benefit in heavily pre-treated advanced breast cancer patients,” stated Dr. William V. Williams, BriaCell’s President & CEO. “We interpret these results to offer a potential opportunity for treatment in otherwise terminal patients. It’s very important to emphasize that these responses and clinical benefit occurred in women with advanced-stage breast cancer who have exhausted other treatment options.”
More great news from BriaCell Therapeutics Corp. (Nasdaq: BCTX)
BriaCell Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation Progressing.
Read all about it here: https://bit.ly/3MRD6bl
#Nasdaq #biotech #oncology #cancer #medical #stocks #stockstowatch #healthcare
BriaCell Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation Progressing.
Phase II efficacy portion of the study, under FDA’s fast track designation, now underway with survival data and clinical benefit being compiled.
Read all about it here: https://bit.ly/3MRD6bl
#oncology #cancer #medical #stocks #stockstowatch #healthcare
More great news from BriaCell Therapeutics Corp. (Nasdaq: BCTX)
BriaCell Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation Progressing.
Read all about it here: https://bit.ly/3MRD6bl
#Nasdaq #biotech #oncology #cancer #medical #stocks #stockstowatch #healthcare
BriaCell Therapeutics Corp. (Nasdaq: BCTX) Announces New Clinical Trial Site to Bring Novel Cancer Treatments to Advanced Breast Cancer Patients!
Check out their press release here for all of the details: https://bit.ly/3yz4FjA
#Nasdaq #Stocks #biotech #StocksToWatch